The FDA said it does not plan to take action against GLP-1 compounders for certain violations while it re-evaluates Eli Lilly’s (LLY) Zepbound drug, Endpoints News’ Nicole DeFeudis reports. The administration is rethinking the tirzepatide shortage, the author notes. Shares of Hims & Hers Health (HIMS), which sells GLP-1 medications, are up 1.9% in afternoon trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Piper says trial suggests Lilly ‘liked what it saw,’ positive for Scholar Rock
- Uber said to consider Expedia bid, CSX posts Q3 miss: Morning Buzz
- Uber downgraded, Zoom Video upgraded: Wall Street’s top analyst calls
- Eli Lilly initiated with an Outperform at Bernstein
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
